Tuesday, June 2, 2026 | 8:00–9:00 PM ET
Activity Description
Rapid advances in the understanding of chronic inflammatory demyelinating polyneuropathy (CIDP) immunopathophysiology—particularly the role of IgG autoantibodies—have accelerated the development of novel biologic therapies, expanding the therapeutic landscape for this complex condition. As these options continue to emerge, clinicians are navigating an evolving evidence base that informs their mechanisms of action, safety considerations, and role within existing treatment paradigms.
New and Emerging Biologic Treatments in CIDP: Mechanisms, Efficacy, Safety, and Clinical Implementation is the fourth of five sessions in the CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes series. Delivered through the Project ECHO® collaborative learning model, this session examines emerging biologic therapies in the context of established treatments. Through expert-led, case-based discussions, participants will explore diagnostic considerations, evidence-informed treatment selection, and collaborative care strategies designed to support improved long-term outcomes and quality of life for individuals living with CIDP.
This Project ECHO® series is built around de-identified cases submitted by participants, reflecting real diagnostic and management challenges from everyday neurology practice. Case should contain de-identified info and submitters are expected to present their case. Case presenters will receive an honorarium.
Cases should be U.S. only and from direct patient care (no hypothetical or simulated cases).
Learning Objective
Speaker
Alain Loriaux, PharmD
(he/him)
Director of Massachusetts Pharmacy Operations
New England Life Care
Woburn, MA
Alain Loriaux, PharmD is a licensed pharmacist in Massachusetts and New Hampshire specializing in home infusion. In his 15 years with New England Life Care, he has helped to advance home care for the treatment of persons who inject drugs and helped to establish the Specialty Pharmacy program at New England Life Care, servicing Maine, Vermont, New Hampshire, Connecticut, Massachusetts and Rhode Island. Dr. Loriaux has been committed to assisting the transition of patients from hospital beds to their homes with the goal of improving clinical outcomes, reducing healthcare costs and maintaining continuity of care.
Credit Information
Jointly Accredited Provider
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME)
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
IPCE
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physician Associates (AAPA)
Boston University Chobanian & Avedisian School of Medicine, has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Pharmacists (ACPE)
This application-based activity is approved for 1.0 contact hour of continuing pharmacy credit.
Nurses (ANCC)
This activity is designated for 1.0 contact hour of which 1.0 are eligible for pharmacology credit.
Certificate of Participation
This activity was certified for a maximum of 1.0 AMA PRA Category 1 Credit™. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education Credit for learning and change.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
FACULTY PRESENTER
Dr. Loriaux reports no financial relationships to disclose.
FACULTY PLANNERS
Dr. Marks (Chair) reports the following financial relationships:
• Speakers Bureau: argenx
Dr. Caplan reports no financial relationships to disclose.
Maggie Naclerio reports the following financial relationships:
• Advisory Board: 06/2023-present- Margaret Naclerio served on UCB, Inc. Nursing & Advanced Practice Provider Education Strategy Working Group Providing insight toward nursing and APP education material
The following individuals have no financial relationships to disclose:
Linda G. Baer, MSPH, CHCP (Planning Committee)
Alison Li, MPH (Planning Committee)
Mary Gleason, PhD, CHCP (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have been mitigated.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
This activity is supported through an independent educational grant from argenx.